Home > Insider Trading > Filing (0001140361-19-018070)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1781983	Aprea Therapeutics Inc.	APRE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1214496	S Christian Schade	535 Boylston Street Boston MA 02116	President & Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-07	1,000	$15.00	1,000	No	4	P	Indirect	By adult child
Common Stock	Acquisiton	2019-10-07	1,000	$15.00	1,000	No	4	P	Indirect	By adult child
Common Stock	Acquisiton	2019-10-07	1,000	$15.00	1,000	No	4	P	Indirect	By adult child
Common Stock	Acquisiton	2019-10-07	1,000	$15.00	1,000	No	4	P	Indirect	By adult child
Common Stock	Acquisiton	2019-10-07	1,000	$15.00	1,000	No	4	P	Indirect	By adult child
Common Stock	Acquisiton	2019-10-07	1,000	$15.00	1,000	No	4	P	Indirect	By adult child
Common Stock	Acquisiton	2019-10-07	5,000	$15.00	5,000	No	4	P	Indirect	By spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By adult child
No	4	P	Indirect	By adult child
No	4	P	Indirect	By adult child
No	4	P	Indirect	By adult child
No	4	P	Indirect	By adult child
No	4	P	Indirect	By adult child
No	4	P	Indirect	By spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to Buy)	Acquisiton	2019-10-07	306,085	$0.00	306,085	$15.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
306,085		2029-10-02	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	160	Direct

Footnotes

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.